142 related articles for article (PubMed ID: 36822869)
1. [Current status and influencing factors for physicians in different departments prescribing novel hypoglycemic agent with cardiovascular benefits].
Zhou LQ; Zhu D; Xu SL; Zhang RT; Yang LC; Deng XN; Xu L; Dong SJ; Liu W; Wang YT; Liu Y; Xu DX; Zhu YN; Yang J; Tong SM; Tang YD
Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):578-584. PubMed ID: 36822869
[No Abstract] [Full Text] [Related]
2. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
[TBL] [Abstract][Full Text] [Related]
3. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
4. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?
Barth SD; Kostev K; Krensel M; Mathey E; Rathmann W
Exp Clin Endocrinol Diabetes; 2023 Mar; 131(3):153-161. PubMed ID: 35981560
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
6. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
8. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
Deo SV; McAllister DA; Al-Kindi S; Elgudin Y; Chu D; Pell J; Sattar N
Diabetes Care; 2022 Dec; 45(12):3054-3057. PubMed ID: 36256925
[TBL] [Abstract][Full Text] [Related]
9. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
[TBL] [Abstract][Full Text] [Related]
10. Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.
Edwards K; Uruska A; Duda-Sobczak A; Zozulinska-Ziolkiewicz D; Lingvay I
Ther Adv Endocrinol Metab; 2023; 14():20420188231180987. PubMed ID: 37440840
[TBL] [Abstract][Full Text] [Related]
11. Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Nelson AJ; O'Brien EC; Kaltenbach LA; Green JB; Lopes RD; Morse CG; Al-Khalidi HR; Aroda VR; Cavender MA; Gaynor T; Kirk JK; Lingvay I; Magwire ML; McGuire DK; Pak J; Pop-Busui R; Richardson CR; Senyucel C; Kelsey MD; Pagidipati NJ; Granger CB
JAMA Netw Open; 2022 Feb; 5(2):e2148030. PubMed ID: 35175345
[TBL] [Abstract][Full Text] [Related]
12. Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.
Arnold SV; Gosch K; Kosiborod M; Wong ND; Sperling LS; Newman JD; Gamble CL; Hamersky C; Rajpura J; Vaduganathan M
Am Heart J; 2023 Sep; 263():104-111. PubMed ID: 37164146
[TBL] [Abstract][Full Text] [Related]
13. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.
Rodriguez-Valadez JM; Tahsin M; Fleischmann KE; Masharani U; Yeboah J; Park M; Li L; Weber E; Li Y; Berkalieva A; Max W; Hunink MGM; Ferket BS
Diabetes Care; 2023 Jun; 46(6):1300-1310. PubMed ID: 37220263
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
[TBL] [Abstract][Full Text] [Related]
16. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB
Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476
[TBL] [Abstract][Full Text] [Related]
17. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
[TBL] [Abstract][Full Text] [Related]
18. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.
Arnold SV; Tang F; Cooper A; Chen H; Gomes MB; Rathmann W; Shimomura I; Vora J; Watada H; Khunti K; Kosiborod M
BMC Endocr Disord; 2022 Apr; 22(1):111. PubMed ID: 35473607
[TBL] [Abstract][Full Text] [Related]
19. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
Gao Y; Peterson E; Pagidipati N
Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
[TBL] [Abstract][Full Text] [Related]
20. New Diabetes Guidelines: Impact on Eligibility for Sodium-glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada.
Bodoarca R; Yeung RO; Lau D
Can J Diabetes; 2022 Apr; ():. PubMed ID: 35940961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
